Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma

References

• Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008; 19: 1146–1153
   PubMed Web of Science ®Google Scholar
• Marrelli D, Roviello F, De Stefano A, Fotia G, Giliberto C, Garosi L, Pinto E. Risk factors for liver metastases after curative surgical procedures for gastric cancer: A prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004; 198: 51–58
   PubMedGoogle Scholar
• Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002; 235: 86–91
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: An analysis of a 17-year experience with 22 patients. Surgery 2003; 133: 507–511
   PubMedGoogle Scholar
• Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534–539
   PubMedGoogle Scholar
• Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Mühlbacher F, Jakesz R, Längle F. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg 2002; 6: 682–689
   PubMed Web of Science ®Google Scholar
• Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, Yamaguchi T. Liver resection for metastatic gastric cancer: Experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 2007; 37: 836–842
   PubMedGoogle Scholar
• Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215–221
   PubMed Web of Science ®Google Scholar
• Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?. Oncologist 2008; 13: 794–806
   PubMedGoogle Scholar
• Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903–2909
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Matuki N, Sakuma H, Katayama K, Sawa T, Fujimura T, Ohyama S, Miwa K, Miyazaki I, Tanaka M, et al. Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases. Surg Today 1992; 22: 253–259
   PubMedGoogle Scholar
• Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, Roviello F, de Manzoni G, Nitti D, Giulini SM. Metachronous hepatic metastases from gastric carcinoma: A multicentric survey. Eur J Surg Oncol 2009; 35: 486–491
   PubMedGoogle Scholar
• Kumada T, Arai Y, Itoh K, Takayasu Y, Nakamura K, Ariyoshi Y, Tajima K. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. Oncology 1999; 57: 216–223
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54–59
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991–4997
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–2657
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ohyama S, Kamata T, Fujimura T, Kimura H, Matsuki N, Sakuma H, Sawa T, Katayama K, Hasegawa H, et al. Multivariate analysis of gastric cancer patients with liver metastases. Gan To Kagaku Ryoho 1990; 17: 2063–2069
   PubMedGoogle Scholar
• Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10: 49–58
   PubMed Web of Science ®Google Scholar
• Kang GH, Kim GS, Lee HR, Yuh YJ, Kim SR. A Phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer. Cancer Res Treat 2008; 40: 106–110
   PubMedGoogle Scholar
• Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg 2006; 141: 460–466, discussion 466–467
   PubMedGoogle Scholar
• Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59–71
   PubMed Web of Science ®Google Scholar
• Kornprat P, Jarnagin WR, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 2007; 142: 1087–1092
   PubMedGoogle Scholar
• Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90: 1240–1243
   PubMed Web of Science ®Google Scholar
• Garrean Sean JH, Saied Abdul, Helton WS, Espat NJ. Radiofreqency ablation of primary and metastatic liver tumors: A critical review of the literature. Am J Surg 2008; 195: 508–520
   PubMedGoogle Scholar
• Bremers AJ, Ruers TJ. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. Eur J Surg Oncol 2007; 33: 752–756
   PubMedGoogle Scholar
• Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007; 33: 67–71
   PubMed Web of Science ®Google Scholar
• Rhim H. Review of Asian experience of thermal ablation techniques and clinical practice. Int J Hyperthermia 2004; 20: 699–712
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, Kitamura H, Ikegami T, Miyagawa SI, Kawasaki S. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol 2001; 96: 3178–3184
   PubMedGoogle Scholar
• Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001; 181: 279–283
   PubMed Web of Science ®Google Scholar
• Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL. Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery 1993; 114: 799–805, discussion 804–795
   PubMedGoogle Scholar
• Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, Shiobara M, Ohtsuka M, Sasada K, Shimizu Y, et al. Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 1997; 92: 490–493
   PubMed Web of Science ®Google Scholar
• Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M, Theodore C, Bonvalot S, Lasser P. Resection of liver metastases from a noncolorectal primary: Indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187: 487–493
   PubMed Web of Science ®Google Scholar
• Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978; 135: 389–394
   PubMed Web of Science ®Google Scholar
• Harrison LE, Brennan MF, Newman E, Fortner JG, Picardo A, Blumgart LH, Fong Y. Hepatic resection for noncolorectal, nonneuroendocrine metastases: A fifteen-year experience with ninety-six patients. Surgery 1997; 121: 625–632
   PubMed Web of Science ®Google Scholar
• An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, Kim S. Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J 2008; 49: 1046–1051
   PubMed Web of Science ®Google Scholar
• Kosaka T, Imaizumi H, Kamei K, Usami K, Nakano Y, Ueno K, Takashima S. A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy. Gan To Kagaku Ryoho 2004; 31: 1737–1739
   PubMedGoogle Scholar
• Carditello A, Scisca C, Stilo F, Parisi A, Basile M. The possible role of radiofrequency as complementary treatment of locally advanced gastric cancer. Annali italiani di chirurgia 2005; 76: 39–41
   PubMedGoogle Scholar
• AJCC Cancer Staging Manual. 6th edn. New York, NY: Springer, 2002, pp. 99–106.
   Google Scholar
• Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, III, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT, Jr, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20: S377–390
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216
   PubMed Web of Science ®Google Scholar
• Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003; 14: S199–202
   PubMed Web of Science ®Google Scholar
• Fumoleau P. Treatment of patients with liver metastases. Anticancer Drugs 1996; 7: S21–23
   PubMedGoogle Scholar
• Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E. The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: A pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 2007; 17: 282–284
   PubMedGoogle Scholar
• Schildberg FW, Meyer G, Piltz S, Koebe HG. Surgical treatment of tumor metastases: General considerations and results. Surg Today 1995; 25: 1–10
   PubMedGoogle Scholar
• Ribeiro MA, Jr, Rodrigues JJ, Habr-Gama A, Chaib E, D'Ipolitto G, Fonseca AZ, Saad WA, Jr, Saad WA. Radiofrequency ablation of primary and metastatic liver tumors–4 years experience. Hepatogastroenterology 2007; 54: 1170–1175
   PubMedGoogle Scholar
• Mertyna P, Dewhirst MW, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: The effect of distance and baseline temperature on thermal dose required for coagulation. Int J Hyperthermia 2008; 24: 550–559
   PubMed Web of Science ®Google Scholar
• Sorensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: Long-term survival. Acta Radiol 2007; 48: 253–258
   PubMed Web of Science ®Google Scholar
• Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559–565, discussion 565–557
   PubMed Web of Science ®Google Scholar
• Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial?. Ann Surg Oncol 2008; 15: 144–157
   PubMed Web of Science ®Google Scholar
• Leen E, Horgan PG. Radiofrequency ablation of colorectal liver metastases. Surg Oncol 2007; 16: 47–51
   PubMedGoogle Scholar
• Rasmussen F. Radiofrequency ablation of liver metastases improves the survival rate of patients with metastatic colorectal disease. Acta Radiol 2007; 48: 250–251
   PubMed Web of Science ®Google Scholar
• Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol 2007; 17: 2062–2070
   PubMed Web of Science ®Google Scholar
• Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, Hachiya O, Hirai I, Kimura W. Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg 2009; 16: 493–501
   PubMedGoogle Scholar
• Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, Tokunaga M, Nagaie T. Hepatic resection for the treatment of liver metastases in gastric carcinoma: Review of the literature. HPB (Oxford) 2006; 8: 89–92
   PubMedGoogle Scholar